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ABSTRACT
The Epstein–Barr virus (EBV)-encoded latent mem-
brane protein-1 (LMP1), a functional homologue of
the tumor necrosis factor receptor family, substan-
tially contributes to EBV’s oncogenic potential by
activating nuclear factor-iB (NF-iB). miR-155 is an
oncogenic miRNA critical for B-cell maturation and
immunoglobulin production in response to antigen.
We report that miR-155 expression is much higher in
EBV-immortalized B cells than in EBV-negative
B cells. LMP1, but not LMP2, up-regulated the
expression of miR-155, when transfected in EBV-
negative B cells. We analyzed two putative NF-iB
binding sites in the miR-155 promoter; both sites
recruited NF-iB complex, in nuclear extract from
EBV-immortalized cells. The exogenous expression
of LMP1, in EBV-negative background, is temporally
correlated to induction of p65 with binding on both
NF-iB sites and with miR-155 overexpression. The
induction of p65 binding together with increased
RNA polymerase II binding, confirms that LMP1-
mediated activation of miR-155 occurs transcrip-
tionally. In reporter assays, miR-155 promoter lack-
ing NF-iB binding sites was no longer activated
by LMP1 expression and an intact AP1 site is
needed to attain maximum activation. Finally, we
demonstrate that LMP1-mediated activation of
miR-155 in an EBV-negative background correlates
with reduction of protein PU.1, which is a possible
miR target.
INTRODUCTION
Epstein–Barr virus (EBV), which infects over 90% of the
adults, appears to have evolved to exploit the normal biol-
ogy of B-cell development in order to persist as a life-long
asymptomatic infection. However, EBV can contribute to
oncogenesis. Indeed, it is frequently found in Burkitt’s
lymphoma, Hodgkin’s lymphoma, nasopharyngeal carci-
noma and lymphoproliferative diseases in immune-
suppressed individuals (1,2). EBV-related oncogenesis is
principally associated with latency during which only a
limited subset of the full repertoire of viral genes are tran-
scribed. In addition to protein-coding genes, the non-
coding RNAs EBER1, EBER2 and a set of EBV-encoded
microRNAs (miRNAs) are expressed in all three forms of
latency (2). Of the genes expressed during viral latency in
EBV-associated diseases, LMP1 is the one most impli-
cated in tumor formation (3,4). LMP1 is invariably
expressed in Burkitt’s lymphoma, it is required for EBV-
mediated transformation of lymphocytes in vitro and it
transforms rodent ﬁbroblasts. Moreover, transgenic mice
expressing LMP1 under the control of an immunoglobulin
promoter develop B lymphocyte tumors more frequently
than wild-type mice (3).
LMP1 is a six-transmembrane constitutively active sig-
naling molecule that functionally mimics members of the
cellular tumor necrosis factor receptor (TNFR) family.
While the transmembrane domains are required for aggre-
gation and constitutive activation of LMP1 (5–8), two
cytoplasmic domains, i.e. the C-terminal activator regions
1 and 2 (CTAR-1 and -2), are critical for the transforming
properties of LMP1 (9–12). Together, these signaling
domains act through cellular TNFR-associated factors
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three transcription factors, namely, nuclear factor-kB
(NF-kB), activator transcription factor-2 (ATF)-2 and
AP-1, via c-Jun N-terminal kinase (JNK) (8–12). By
manipulating these cell-signaling pathways, LMP1 aﬀects
host cellular processes that regulate cell proliferation,
migration and apoptosis, thereby contributing to cellular
immortalization and tumorigenesis.
The miR-155 is processed from a primary transcript,
known as ‘BIC’ (B-cell integration cluster), whose
upstream region was originally found to be a frequent
site of integration of the avian leucosis virus in lymphomas
(13). Transgenic mouse studies demonstrated that B-cell
targeted expression of BIC leads to the development
of B-cell malignancies (14). Furthermore, a number of
miRNA proﬁling studies have shown elevated levels of
miR-155 in a wide array of cancers including lymphomas
(14–19). miR-155 is one of the miRNAs most frequently
implicated in cancers. It plays a critical role in lymphocyte
activation in vivo (20,21) and is induced by a variety of
immune cell stimuli, i.e. toll-like receptor (TLR) ligands,
TNF-a, interferon-beta (IFN-b) and antigens [B-cell
receptor (BCR) engagement] (16,22). The mechanism by
whichmiR-155isregulatedafterTLRandIFNsignaling in
macrophages is still unknown. Here we show that LMP1
upregulatestheexpressionofmiR-155mainlybyactivating
the NF-kB pathway, which suggests that miR-155 can
cooperate in the EBV-mediated transformation of B cells.
MATERIALS AND METHODS
Cell culture
EBV-negative human B cells (DeFew) and EBV-
immortalized human B cells MC3 (kindly provided by
Prof. Giuseppe Scala, University ‘Magna Grecia’
Catanzaro) Devozione, Cap (kindly provided by Dr
Giuseppina Ruggiero, University ‘Federico II’, Naples),
were cultured in RPMI 1640 medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (Invitrogen) and 2mM glutamine. Murine
embryonic ﬁbroblasts (MEFs) and HEK 293 referred to as
LinX, stably transfected with the helper vector, [LinX cell
line, Openbiosystem, (http://www.openbiosystems.com/
RNAi/LinX/)] were cultured in DMEM medium
(GIBCO-Invitrogen) supplemented with 10% fetal
bovine serum (Invitrogen) and 2mM glutamine.
RNA preparation and northernblot
Total RNA was extracted using Trizol reagent
(Invitrogen) according to supplier’s protocol. Northern
blot analysis was carried out on 15mg of total RNAs.
Brieﬂy, all RNA samples were dissolved in loading
buﬀer [0.05% bromophenol blue, 0.05% cyanol, 5%
Ficoll (type 400), 80% formamide and 7M urea], boiled
for 5min at 958C and loaded onto 15% polyacrylamide
gel under denaturizing conditions [15% acrylamide-bis-
acrylamide 19/1, 45mM Tris, 45mM boric acid, 1mM
EDTA pH 8, 7M urea, 0.01% N,N,N0,N0-tetramethyl-
ethylenediamine (TEMED) and 0.1% ammonium persul-
fate (APS)]. Samples were resolved by electrophoresis for
90min at 150V and transferred onto nylon membranes
(Hybond N
+, Amersham/GE Healthcare, Little
Chalfont, UK) by capillary blot. The nylon membranes
were then equilibrated in 1M NaCl and pre-hybridized
in 6  SSC, 5  Denhart’s solution (1  Denhart’s solu-
tion=0.1% Ficoll, 0.1% polyvinyl pyrrolydone and
0.1% bovine serum albumin), 5mg/ml of sheared
salmon sperm ds-DNA (Ambion, Austin TX, USA) at
428C for 2h. After pre-hybridization, 1 10
6CPM/ml of
[g
32P-ATP] radiolabeled oligonucleotide probe was added
and the hybridization carried out overnight at 428C. The
membranes were washed twice in 2  SSC, 1% SDS at
428C for 30min and exposed either by autoradiography
or by phosphorimage screen (Amersham/GE Healthcare).
The signals were quantiﬁed with image-scanning or by
Image-J software analysis.
Westernblot analysis
The cell pellets were resuspended in 1ml of lysis buﬀer
[10mM HEPES, pH 7.4, 150mM KCl, 1mM EDTA pH
8, 1% Triton X-100, 1mM DTT, 1mM orthovadanate,
1mM NaF and protease inhibitor cocktail (Roche, Basel,
Switzerland)] at 48C for 20min. Then, 40mg of proteins, of
each sample, were resuspended in Laemmli buﬀer (23) and
resolved by SDS–PAGE (running gel: 0.4M Tris, pH 8.8,
12% acrylamide/bis-acrylamide 37/1, 0.1% SDS, 0.01%
TEMED, 0.1% APS; staking gel: 0.07M Tris pH 6.8,
5% acrylamide/bis-acrylamide 37/1, 0.1% SDS, 0.01%
TEMED, 0.1% APS). The proteins were transferred
onto nitrocellulose membranes (Hybond ECL, Ame-
sham/GE Healthcare) by electroblotting. Membranes
were blocked in 5% of ‘non-fat milk’ (BioRad, Hercules
CA, USA) 0.5% BSA in phosphate buﬀer solution for 2h
at room temperature and immunoblotted with monoclo-
nal antibody against LMP1 (kindly provided by Dr Dong
Yun Lee, McArdle Laboratory for Cancer Research, Uni-
versity of Wisconsin-Madison), mouse polyclonal anti-
body against g-tubulin (Sigma Chemical Company, St
Louis MO, USA) mouse monoclonal antibody against
p65 (SantaCruz, CA, USA), rabbit polyclonal antibody
against IkBa (SantaCruz), rabbit polyclonal against H3
(SantaCruz) or rabbit polyclonal antibody against PU.1
(Santa Cruz). Speciﬁc secondary antibodies (Sigma Che-
mical Company), horse-radish peroxidase conjugated,
were used for protein detection by enhanced chemilumi-
nescence (ECL, Amesham/GE Healthcare) followed by
autoradiography (Hyperﬁlm ECL, Amesham/GE Health-
care). We used the Image-J software for densitometric
analysis.
Cloning andmutagenesis of BIC/miR-155 promoter
The human BIC/miR-155 promoter region extending from
1783 to 1, from 1380 to 1, from 1065 to 1 relative to the
start site was isolated from MC3 genomic DNA by PCR
using the following primers:
Fw AGCTGAGCTCGAAAGGTCACCCTAGAATTG
( 1783),
Fw AGCTGAGCTCGATCTGGCACATGGTAAATG
( 1380),
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( 1065),
Rev CATGAAGCTTATCCGCTCCCTTCCCGAG
(+1).
The isolated fragments were digested with SacI and
HindIII and cloned into SacI and HindIII cut
pGL3basic (Promega, Madison, WI, USA). The entire
promoter region was sequenced and no discrepancies
were identiﬁed relative to the Genebank genomic sequence
(http://www.ncbi.nlm.nih.gov/Genbank/).
Mutagenesis of the pLuc1380 and pLuc1783 reporter
plasmid was carried out with the ‘Expand Long
Template PCR system’ (Roche) and the following oligo-
nucleotides: 50-GTA AAT TAA GTA CTA TGC TCG
AGC CAG CTC TGA CAT G-30 and 50-CAT AGT
ACT TAA TTT ACA GAT GGC TCA GGT TGG
TTA AG-30 (NF-kB1), Fw 50-CAACCTAGAATGAGA
AATGCTCGAGTCAGAAAGGCATTGTAGG-30 and
Rev 50-CATTTCTCATTCTAGGTTGAACTATACCTC
CCTTCTCCCAGTG-30 (NF-kB2), 50-GGC GCC TGG
TCG GTT ATC TCG AGC AAG TGA GTT ATA
AAA-30 and 50-ATA ACC GAC CAG GCG CCT TTT
CTG CAA CCC-30 (AP-1). In each case, the core tran-
scription factor binding site was replaced by a XhoI restric-
tion site. Mutations were initially screened by digesting
with XhoI and then veriﬁed by sequence analysis.
Reporter analysis
For each reporter plasmid, 2 10
6 MEFs were distributed
in 6cm dish plates containing 5ml RPMI1640 (Invitrogen)
10% FBS (Cambrex, East Rutherford, NJ, USA), 2mM
glutamine. FuGene (Roche) of 6ml were added to 300mlo f
DMEM and incubated for 5min at room temperature.
Each reporter vector of 0.5mg plus 0.2mgo fb-galactosi-
dase vector were then added to the mixture, the tubes were
shacked and incubated at room temperature for 15min.
For each transfection, the mixtures were then added to
each plate and plates were incubated at 378C, 5% CO2
for 48h. Cells were harvested 48h later and assayed for
luciferase activity. Results are presented as average of
three independent experiments.
For each reporter plasmid, 2 10
6 DeFew were distrib-
uted in 6cm dish plates containing 5ml RPMI1640
(Invitrogen) 10% FBS (Cambrex), 4mM glutamine.
FuGene (Roche) of 8ml were added to 300ml of DMEM
and incubated for 5min at room temperature. Each repor-
ter vector of 1mg plus 0.5mgo fb-galactosidase vector were
then added to the mixture, the tubes were shacked and
incubated at room temperature for 15min. For each trans-
fection, the mixtures were then added to each plate and
plates were incubated at 378C, 5% CO2. After 6h each
sample was split in two, and one of them was treated
with 10ng/ml of phorbol myristoylated acetate (PMA).
Cells were harvested 48h later and assayed for luciferase
activity. Results are presented as average of three indepen-
dent experiments.
Chromatin immunoprecipitation assay
MC3 or DeFew cells (5 10
6 cells) were exposed to 1%
formaldehyde for 10min at 378C to obtain protein–DNA
cross-linking. The nuclear fraction was sonicated to yield
chromatin fragments of 200–1000bp; 5% of the total
volume was removed from each sample and used as
the input fraction. Chromatin was pre-cleared by pre-
incubation with a DNA salmon sperm/protein A-agarose
50% slurry (Upstate, Temecula, CA, USA) for 1h at 48C.
The agarose was centrifuged, and the pre-cleared chroma-
tin supernatant was incubated with the antibodies (3mg)
against RNA pol II (mAb anti RNA polymerase II, Active
Motif, Rixensart, Belgium), p50 or p65 (pAb anti p50 or
pAb anti p65, kindly provided by Dr N. Rice, Frederick
Cancer Research and Development Center, Frederick,
MD, USA), against histone 3 (pAb anti H3, SantaCruz),
overnight at 48C. The protein–DNA-antibody complexes
were collected by the addition of the salmon sperm DNA–
protein A-agarose (2h at 48C) and washed, and protein–
DNA cross-linking was reversed (4h at 658C). DNA was
puriﬁed by phenol/chloroform extraction and ethanol pre-
cipitation and aliquots (25%) of the puriﬁed materials
underwent PCR (5min at 948C, 1min at 948C, 1min at
528C, 1min at 728C for 40 cycles, 5min at 728C).
Preparation of nuclear extracts and electrophoresis
mobility shiftassay
MC3 cells (5- to 6 10
6 cells) were washed with cold phos-
phate buﬀered saline and harvested. The cell pellet was
resuspended in extraction buﬀer containing 10mM
HEPES, pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.1mM
EGTA, 0.5mM DTT, 0.5mM PMSF, 10mg/ml aprotinin,
10mg/ml leupeptin, passed through a needle, kept on ice
for 45min, and centrifuged (15min at 14000r.p.m. at
48C). The nuclear pellet was then resuspended in high
salt extraction buﬀer containing 10mM HEPES, pH 7.9,
0.4mM NaCl, 1.5mM MgCl2, 0.1mM EGTA, 0.5mM
DTT, 0.5mM phenylmethylsulfonyl ﬂuoride, 10mg/ml
aprotinin, 10mg/ml leupeptin and incubated for 45min
at 48C. The nuclear extract supernatant was obtained by
centrifugation (30min at 14000r.p.m. at 48C), protein
concentration was determined and 5mg aliquots were
stored at  808C until used. Double-stranded synthetic
oligonucleotides were radiolabeled using [
g32P]ATP
(3000Ci mmol
–1; Amersham Biosciences) and T4 polynu-
cleotide kinase (Fermentas, Burlington, ON, Canada).
The binding reaction was carried out for 20min at room
temperature with 5mg of nuclear proteins in 10% glycerol,
60mM KC1, 1mM EDTA, 1mM dithiothreitol and
0.250mg/ml poly[dI–dC] containing 50000 cpm of radiola-
beled probe and a 80-fold molar excess of unlabeled com-
petitor oligonucleotide when indicated. For supershift
experiments, 4mg of speciﬁc anti-p65 or anti-p50 were
added to the binding reaction and incubated for 30min,
after which we added the radiolabeled probe. DNA–
protein complexes were separated by 5% non-denaturing
polyacrylamide gel and revealed by either autoradiogra-
phy or phosphorimage screen (Amersham Biosciences).
Transient transfection
DeFew cells (3 10
6 cells) were centrifuged, washed in
PBS and resuspended in 300ml of electroporation
medium (RPMI 1640 medium, 20% FBS and 2mM
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expressing LMP1 (pcDNA3-LMP1), or LMP2
(pcDNA3-LMP2) or both and subsequently transferred
in electroporation cuvette. Cells were electroporated
twice at 220V, 960mFa and incubated 5min on ice. Cells
were plated in 10ml of RPMI 1640 medium, 10%
FBS and 2mM glutamine for 2 days. After 2 days, they
were harvested and assayed for miR-155 and LMP1
expression.
Viral generation, infection and timecourse
The retroviral vector LMP1pBABE-puro was kindly pro-
vided by Prof. Eiji Hara (University of Tokushima,
Japan). LinX cell line, stably transfected with the helper
vector, were grown in DMEM medium 10% FBS, 2mM
glutamine and 100mg/ml hygromicin. Transfections with
LMP1pBABEpuro or pBABEpuro (empty vector) were as
follows: 6cm plate of semi-conﬂuent (about 1 10
6 cells)
cells were transfected and 7.5mg of DNA vector incubated
in 20ml of FuGene and incubated in 4ml of medium with-
out antibiotic for 24h. After incubation, the medium was
harvested, replaced with 4ml of fresh medium and the
LinX cells incubated for 24h for a second round of viral
generation.
DeFew cells (4 10
6 cells) were centrifuged, washed in
PBS and resuspended in 4ml of virus containing medium
plus 4mg/ml of Polybrene (Sigma). The infection was per-
formed by spinoculation, namely by centrifugation at
3500r.p.m. for 90min at 208C. After centrifugation, the
cells were resuspended in 10ml of RPMI and incubated
at 378C, 5% CO2. Twenty-four hours later, the cells
underwent a second round of infection. After 48h, cells
were treated with 1mg/ml of puromicine to start selection
of positive clones.
For the time course, DeFew cells (4 10
6 cells) were
centrifuged, washed in PBS and resuspended in 12ml of
virus containing medium plus 12mg/ml of Polybrene
(Sigma). The infection was performed by spinoculation,
namely by centrifugation at 3500r.p.m. for 90min at
208C. After centrifugation, the cells were resuspended in
10ml of RPMI and incubated at 378C, 5% CO2. Twenty-
four hours later, 1mg/ml of puromocine was added to cells
to start selection. Cells were harvested at 6, 24, 48 and 72h
after infection and assayed for miR-155 and LMP1
expression.
Transient transfection ofMC3
MC3 cells (3 10
6 cells) were centrifuged, washed in PBS
and resuspended in 300ml of electroporation medium
(RPMI 1640 medium, 20% FBS and 2mM glutamine).
Cells were mixed in a tube with 20mg of pRc/CMV-HA-
IkBa-S32/36A (kindly provided by Prof. Ileana Quinto,
University Magna Grecia, Catanzaro) and subsequently
put in electroporation cuvette. Cells were electroporated
twice at 220V, 960mFa and incubated 5min on ice. Cells
were plated in 10ml of RPMI 1640 medium, 10% FBS
and 4mM glutamine for 2 days. After 2 days, they were
harvested and assayed for miR-155, p65 and IkBa
expression.
RESULTS
The expression of mir-155 isregulated by LMP1
We measured miR-155 expression in three EBV-
immortalized cell lines (MC3, Devozione and Cap) and in
two EBV-negative B-cell lines (EW36 and DeFew), a T-cell
lymphoma cell line (Jurkat) and NB4 from acute promye-
locytic leukemia. As shown in Figure 1, miR-155 was
expressed at relevant levels only in the EBV-positive cells
according to Mrazek et al. (24). In the EBV-negative
B cells, miR-155 expression was not aﬀected by stable
transfection of the EBV nuclear factor 2 (EBNA2)
(Figure 1), a viral transacting factor that activates the
expression of such cellular and viral promoters as the
HIV-1 long terminal repeat (25) and the interleukin-6
promoter (26).
To evaluate whether LMP1 induces miR activation, we
transiently transfected a vector expressing LMP1, LMP2
or both in DeFew cells (EVB-negative B cells). There was
a 1.6-fold induction of miR-155 expression in LMP1-
transfected cells, no induction in LMP2-transfected cells
and a 1.7-fold induction in cells transfected with LMP1
and LMP2 (Figure 2A and B). The signiﬁcance of this
ﬁnding is underestimated because only a few cells were
transfected by LMP1 expression vector. Indeed, LMP1
was much lower in transiently transfected DeFew cells
than in MC3 cells (Figure 2C). To overcome this problem,
we infected the DeFew cells with a retroviral vector
expressing LMP1 (pBABEpuroLMP1). As shown in
Figure 2D, we obtained a higher expression of LMP1, at
72h post-infection, resulting in about 3.5-fold induction of
Figure 1. miR-155 is upregulated in EBV-immortalized cell lines.
Northern blot analysis on total RNAs obtained from 9 cell lines. The
blot was analyzed for the expression of mature miR-155 and normal-
ized by the ubiquitous small nuclear RNA U6. Note that basal levels of
miR-155 expression in DeFew cells are not visible in this blot due to
the brief exposure.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6611miR-155 expression compared to DeFew cells infected
with the empty virus (Figure 2E and F).
miR-155expression canbe driven through
activationof two NF-iBelements in the
BIC/miR-155 promoter
The foregoing results suggested that the LMP1-mediated
induction of miR-155 occurred via a transcriptional
mechanism. A recent study showed that the miR-155 pro-
moter contains an AP-1 active site, located at 40nt
upstream from the TATA box and a NF-kB site located
at 1150nt upstream from the transcription starting site
(27). The AP-1 active site plays a key role in activation
of miR-155 expression induced by BCR (27). To identify
potential cis-elements active on miR-155, we isolated a
promoter region of  1.9kb of the BIC gene, which
encodes miR-155 (28), from MC3 cells and cloned it
into a luciferase reporter plasmid. We looked for cis-
element homologies using TESS (http://www.cbil.upe
nn.edu/cgi-bin/tess) or TFSEARCH (http://www.cbrc.jp/
research/db/TFSEARCH.html), and identiﬁed some
potential transcription factor binding sites, among
which, an additional NF-kB site located at 1697nt
upstream from the transcription starting site (Supplemen-
tary Material Figure 1). Because NF-kB signaling plays a
central role in B-cell physiology, we focused on the two
NF-kB cis-elements.
We next examined by northern blot the induction of
miR-155 expression in DeFew cells treated with PMA,
which induces NF-kB by activating protein kinase C
(PKC) and related phosphorylation of inhibitor-kBa
(IkBa), thereby leading to its degradation (29). PMA
(25ng/ml) increased miR-155 expression by about 3-fold
(Figure 3A and B); miR-155 expression peaked 36h after
treatment and decreased thereafter (Figure 3A and C).
The latter ﬁnding is in accordance with the pattern of
PKC-activated NF-kB expression (29).
The NF-iB elements inthe BIC/miR-155 promoter
bind NF-iBfactorsin vitro and invivoin MC3 cells
To determine the activity of the two NF-kB elements iden-
tiﬁed in the miR-155 promoter, we performed EMSA
using nuclear extracts from MC3 cells. Brieﬂy, the nuclear
extracts were incubated with dsDNA oligonucleotides
identical to the sequence of the NF-kB site 1 ( 1150) or
2(  1697). Both sites underwent an electrophoretic mobil-
ity shift, which disappeared when we used a 80-fold molar
cold competitor, but not when we used the same amount
of a mutant competitor that is not bound by NF-kB com-
plexes (Figure 4A). There was a supershift when the
nuclear proteins were pre-incubated with antibodies
against p65/RelA or p50, two members of the NF-kB
family (Figure 4A). Because LMP1 could activate the
p52/p65 NF-kB complex (non-canonical pathway)
(30,31), we repeated the experiment using an anti p52 anti-
body, and found no supershift under these conditions
(data not shown). In line with the hypothesis that
the canonical NF-kB pathway is involved in the
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Figure 2. LMP1 enhances the expression of miR-155 in an EBV-negative B-cell line. (A) A representative northern blot analysis on total RNAs
obtained from DeFew cells transfected (TF) as indicated or untransfected (UT). The blot was analyzed for the expression of mature miR-155 and
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retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of mature miR-155 and normalized by U6. (E) Graphic
representation of the northern blot results as average of three independent experiments. (F) Western blot analysis of the expression of LMP1 upon
infection with the retroviral vector. Input proteins were equalized by detecting the endogeneous g-tubulin.
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miR-155 expression was inhibited in MC3 cell express-
ing an exogenous, undegradable form of IkBa (32),
which is an inhibitor of the canonical NF-kB pathway
(Supplementary Figure 2).
To determine whether the NF-kB p50/p65 complex is
recruited in vivo on the BIC/miR-155 promoter, we exam-
ined the two NF-kB sites by chromatin immunoprecipita-
tion assay (ChIP). We show that p65 but not p50 is
engaged on the two NF-kB sites (Figure 4B). However,
we cannot rule out that p50 contributes to the active com-
plex because it could simply be covered by DNA and p65,
and thus inaccessible to the antibody. RNA pol II drives
miR-155 transcription (33). Therefore, we checked, in the
same experiment if the BIC promoter was also engaged by
the RNA pol II. As shown in Figure 4C we found the
RNA polymerase on the TATA box of BIC promoter
together with p65 (Figure 4C).
LMP1 requires intact NF-iBcis-elements to enhance
miR-155expression
The foregoing experiments provide compelling evidence
that LMP1 drives miR-155 upregulation and that the
miR promoter responds to NF-kB transacting factors.
However, LMP1 can activate two diﬀerent pathways:
the NF-kB pathway and the Jun/Fos (AP-1) pathway
(6,8–10) and the miR-155 promoter has a cis-element
responsive to AP-1 40nt upstream from the start site
(27). Using truncated forms of BIC promoter cloned
upstream the luciferase gene reporter, we observed that
only the ﬁrst 1380nt drive the maximum activation of
the promoter by PMA (Figure 5) or LMP1 (Figure 6).
This could indicate that the NF-kB site 2 is irrelevant
in the LMP1-mediated activation of miR-155. To verify
the eﬀectiveness of the two NF-kB cis-elements in
LMP1-enhanced miR-155 promoter, we used both the
promoters cloned upstream luciferase gene reporter
[pLuc1783 wild-type (wt) and pLuc1380wt]. Sub-
sequently, we mutated NF-kB site 1 (pLuc1783NF-
kB1 and pLuc1380NF-kB), the AP-1 site
(pLuc1783AP-1 and pLuc1380AP-1) and the NF-kB
site 2 (pLuc1783NF-kB2) using site-directed mutagen-
esis. All vectors were used for transfection and reporter
assay in EBV-negative MEF. As shown in Figure 6A,
pLuc1380wt was upregulated by about 5-fold when
cotransfected with a vector expressing LMP1. In the pre-
sence of LMP1, pLuc1380NF-kB expression was about
80-fold less, and the expression of pLuc1380AP-1 about
6-fold less than pLuc1380wt expression (Figure 6A).
These data would suggest that NF-kB site 1 plays a pivo-
tal role in LMP1 activation and that substantial coopera-
tion by the AP-1 site is required to attain maximum
activation. Consistent with these results, NF-kB
seems to be central also for basal levels of miR-155 expres-
sion. Indeed, without LMP1, pLuc1380NF-kB expres-
sion was about 17-fold lower than pLuc1380wt
expression, whereas pLuc1380AP1 was downregulated
by about 3-fold (Figure 6A). When the reporter assays
were repeated using the full-length vector pLuc1783wt,
induction was reduced (about 3-fold), in the presence of
LMP1 compared to pLuc1380wt (compare Figure 6A
and B), which is in line with the results reported in
Figure 5. Surprisingly, all mutated forms of this
vector (pLuc1783NF-kB2, pLuc1783NF-kB1 and
pLuc1783AP-1) were no longer activated by LMP1
expression (Figure 6B). The graph in Figure 6B is pre-
sented in logarithmic scale in order to show that the muta-
tions in both NF-kB sites dramatically reduced the basal
level of miR-155 promoter-driven luciferase expression,
whereas the AP-1 mutation reduced basal levels to
a much lesser extent. The latter observation is consistent
with our data obtained with the truncated promoter.
The expression of LMP1 was checked in each sample
(Figure 6C) for a further normalization of the luciferase
assays.
These data indicate that both NF-kB cis-elements play a
central role in LMP1-mediated activation of the promoter
and may suggest the possible presence of a negative
regulatory region between the two cis-elements.
Figure 3. PMA induces miR-155 expression in a dose- and
time-dependent manner. (A) Left: northern blot analysis of RNAs
from DeFew cells treated with diﬀerent concentrations of PMA;
Right: northern blot analysis of RNAs from DeFew cells at diﬀerent
times upon PMA treatment. The blots were analyzed for the expression
of mature miR-155 and normalized by U6. (B and C) Graphic repre-
sentation of the average of three independent northern blot
experiments.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6613The bindingof p65/RelA to bothNF-iBcis-elements of
miR-155promoter is temporally correlated to LMP1
expression
To determine whether the exogenous expression of
LMP1, in DeFew cells, is correlated temporally with the
upregulation of the endogenous miR-155, we performed a
time-course experiment in DeFew cells infected with
pBABEpuroLMP1 or with the empty vector as control.
Each time point was split into three for western blot,
northern blot and ChIP analyses. LMP1 expression was
observed 24h post-infection and peaked at 72h
(Figure 7A and B), whereas the upregulation of miR-155
occurred at 48h post-infection and increased at 72h
(Figure 7C and D). These results indicate that the upreg-
ulation of miR-155 is temporally dependent on the expres-
sion of LMP1 (Figure 7E).
To further clarify the function of the two NF-kB cis-
elements in the endogenous miR-155 promoter, we per-
formed ChIP analysis followed by semi-quantitative
PCR. There was constitutive binding of p65/RelA on
both NF-kB sites (Figure 8A, left panel and Figure 8B).
This binding did not increase in the cells infected with the
empty vector (Figure 8A, left panel). In contrast, in the
cells expressing LMP1, the binding of p65/RelA on NF-
kB 1 site increased 1.5-fold at 24h and 3.5-fold at 72h
(Figure 8A, left panel and Figure 8B), whereas the binding
of p65/RelA on the NF-kB 2 site increased 1.3-fold at 24h
and 2.5-fold at 72h (Figure 8A, left panel and Figure 8B).
At the same time points, the binding of RNA pol II on
the TATA box of BIC promoter increased in the
LMP1-infected cells but not in the control cells
Figure 4. The two putative NF-kB binding sites are bound by NF-kB complexes in vitro and in vivo in MC3 cells. (A) Electrophoretic mobility shift
assay using nuclear extracts from MC3 cells (EBV-positive cells) on the two NF-kB binding sites. Left panel: NF-kB site 1 ( 1150). Right panel: NF-
kB site 2 ( 1697). WT=80-fold molar cold wild-type competitor; mut=80-fold molar cold mutant competitor; U=80-fold molar cold unspeciﬁc
competitor; p50=supershift with anti NF-kB p50 antibody; p65=supershift with anti NF-kB p65 antibody. Supershift bands are indicated with red
arrows. (B) ChIP assay of chromatin extracted from MC3 cells using polyclonal antibodies directed against the NF-kB p65 or NF-kB p50. After
immunoprecipitation, the DNA samples were puriﬁed and subjected to PCR with speciﬁc primers amplifying the NF-kB site 1 region (right panel) or
NF-kB site 2 region (left panel). MW=molecular weight marker; p65=pAB anti NF-kB p65; p50=pAb anti NF-kB p50; aRab=unspeciﬁc
polyclonal antibody anti rabbit immunoglobulin; IP=input. The red arrows indicate the speciﬁc ampliﬁed band. (C) ChIP assay of chromatin
extracted from MC3 cells using monoclonal antibody directed against the RNA pol II. After immunoprecipitation, the DNA samples were puriﬁed
and subjected to PCR with speciﬁc primers amplifying the TATA box region. MW=molecular weight marker; pol II=mAB anti RNA pol II;
IP=input. The two lanes represent two diﬀerent amounts of input sample used for the PCR; aRab=unspeciﬁc polyclonal antibody anti rabbit
immunoglobulin. The red arrow indicates the speciﬁc ampliﬁed band.
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Figure 5. Truncated form of the BIC promoter (pLuc1380) is the most
inducible by PMA. Luciferase assay performed in De Few cells using
the full-length miR-155 promoter and two truncated forms. The trans-
fected cells were treated or mock treated with 25ng/ml of PMA. In
presence of PMA the truncated form of the BIC promoter (pLuc1380)
reaches the maximum of luciferase activity. The graphic representation
of the luciferase assay is the average of three independent experiments.
6614 Nucleic Acids Research, 2008, Vol. 36, No. 20(Figure 8C left panel). G3PDH was used as negative con-
trol and the assay was normalized against histone H3
(Figure 8A and C, right panel). Taken together, these
data and the results reported in Figure 7 strongly suggest
that LMP1 activates p65 binding on miR-155 promoter
and this lead to upregulation of miR expression.
The protein levelsof transcription factorPU.1 correlates
withLMP1-induced miR-155 expression
It was recently reported that miR-155 targets PU.1
mRNA thereby aﬀecting its translation (35). Hence, we
checked whether the levels of protein PU.1 could be low-
ered by LMP1 activation of miR-155. To this aim, we
infected DeFew cells with the retroviral vector expressing
LMP1 or with the empty vector as control. The results
show a 2-fold decrease of PU.1 protein levels in the
DeFew cells infected with LMP1-expressing vector
versus empty vector (Figure 9A and B). In the same
experiment, we ran a northern blot analysis to evaluate
miR-155 expression. As shown in Figure 9C and D,
miR-155 expression in LMP1-expressing DeFew cells
was 10-fold higher than in the empty vector. Interestingly,
PU-1 levels were very low in EBV-immortalized MC3 cells
overexpressing miR-155
DISCUSSION
microRNAs, like transcription factors, regulate the
expression of several genes post-transcriptionally, and
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Figure 6. NF-kB cis-elements are essential for basal and LMP1-mediated activation of miR-155 pomoter. (A and B) The indicated miR-155 promoter
luciferase vectors were co-transfected with pBABEpuroLMP1 or empty vector and incubated for 48h. Luciferase expression was normalized by
b-gal/mg of total protein and represented as average of three independent experiments. (C) Western blot analysis of LMP1 expression in the
co-transfected MEF cells, normalized by gtubulin.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6615are thus important players in such relevant cellular pro-
cesses as cell growth, diﬀerentiation, cell signaling and
apoptosis [see (11) for a review]. miRNAs themselves are
subjected to ﬁne expression regulation, their transcription
being driven by RNA pol II responsive promoters (33). It
is generally recognized that miRNAs play a central role in
the molecular etiology and maintenance of cancer.
In this study, we describe the activation of miR-155,
which is a potential oncomiR (14), by LMP1, a trans-
membrane EBV protein considered to be the major onco-
protein of EBV. LMP1 is expressed during viral latency
and it activates the signaling pathways NF-kB and AP-1
(12). Using miRNA array, it has been reported that
LMP1-induced the expression of numerous miRNAs,
such as miR-146, whose expression is upregulated by the
LMP1-induced NF-kB pathway (36,37). Here we show
that EBV-infected cells constitutively express high levels
of miR-155, and that the exogenous expression of LMP1
in EBV-negative B cells enhances miR-155 expression in a
time- and dose-dependent manner (Figure 7). Yin et al.
(27) reported that the promoter of the BIC gene encoding
miR-155 contains a conserved AP-1 element 40 bases
upstream from the transcription start site that is essential
for the induction of miR-155 mediated by activation of the
BCR (27). They also identiﬁed a putative NF-kB site at
 1150nt on the BIC promoter whose mutation did not
aﬀect miRNA enhancement by activation of the BCR
(27). We found an additional NF-kB putative binding
site at –1697nt on the BIC promoter. We show that the
endogenous promoter is responsive to PMA (Figure 3), a
well recognized activator of the canonical inhibitor kinase
kinase-dependent (IKK) (29) NF-kB pathway. Moreover,
both putative NF-kB sites were able to bind in vitro the
NF-kB proteins p50 and p65 in nuclear extract from MC3
cells (Figure 4A).
Because LMP1 induces both the canonical IKK-
dependent (30) and non-canonical NF-kB-induced
kinase-dependent (NIK) (31) NF-kB pathways, we tested
whether p52 (an NF-kB protein activated by a non-
canonical pathway) was part of the binding complex,
but we did not detect it. Accordingly, inhibition of the
canonical NF-kB pathway by exogenous expression of
IkBa led to reduced expression of miR-155 in MC3
(Supplementary Figure 2). This could indicate that the
non-canonical pathway is activated only at the beginning
of EBV infection when the virus needs to maximize this
signaling pathway.
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Figure 7. Time-course of LMP1-mediated activation of miR-155. (A) Western blot analysis of protein extracts obtained at indicated times
from DeFew cells infected with pBABEpuroLMP1 or empty vector. The blot was analyzed for the expression of LMP1 and normalized by
g-tub. (B) Graphic representation of the western blot results. (C) Northern blot analysis of RNAs obtained at indicated times from DeFew cells
infected with retroviral vector expressing LMP1 or empty vector. The blot was analyzed for the expression of miR-155 and normalized by U6.
(D) Graphic representation of the northern blot results. (E) Graphic representation of the correlation of miR-155 and LMP1 expression at
indicated times.
6616 Nucleic Acids Research, 2008, Vol. 36, No. 20Furthermore, both the NF-kB sites bound to p65 in vivo
as did the RNA pol II on the TATA box of the BIC
promoter, in MC3, which indicates ongoing miR-155 tran-
scription (Figure 4B and C) suggesting that the two NF-
kB sites are active in an EBV-positive background.
However, PMA- and LMP1-driven induction was higher
with a truncated form of the BIC promoter lacking the
distal site (NF-kB site 2) than with the full-length pro-
moter (Figures 5 and 6). To shield light on the eﬀective-
ness of the two NF-kB cis-elements, we performed
reporter assays using the full length (pLuc1783) or a trun-
cated form (pLuc1380) of miR-155 promoters either wild-
type or mutated in the NF-kB site 1, NF-kB site 2 or
AP-1. Our results indicate that both NF-kB sites are pivo-
tal for basal and LMP1-induced expression of miR-155
(Figure 6). Conversely, mutation of the AP-1 site in the
pLuc1380 reduced the constitutive expression of the pro-
moter, which in fact was still inducible by LMP1 albeit to
a lesser extent (Figure 6). However, mutation of the AP-1
site in the pLuc 1783 abolished the LMP1-induced expres-
sion. Yin et al. [unpublished data in (34)] suggested that
miR-155 promoter contains one or more CpG islands. The
presence of putative CpG as well as cis-elements bound by
negative regulatory protein(s) or promoter secondary
structures could explain why the truncated form of the
promoter, lacking this putative NRE, is inducible at
higher extent by both PMA and LMP1.
Subsequently, we performed time-course experiments in
EBV-negative cells infected with an exogenous LMP1.
Our data show that the expression of LMP1 is temporally
correlated with the activation of p65 binding on both NF-
kB sites (Figure 8), recruitment of RNA pol II and miR-
155 induction (Figures 7 and 8). All data reported give a
clear indication that LMP1 enhances miR-155 expression,
mainly, via activation of the canonical NF-kB pathway.
Our results, together with the previous data reported by
Yin et al. (27), illustrate the exquisite regulation of this
miR by various stimuli, and highlight its importance in
B-cell physiology.
PU.1 is a downstream eﬀector of miR-155 thanks to the
presence of a miR-155 complementary seed sequence in
the 30 UTR of PU.1 mRNA (35). In the latter report,
B cells lacking miR-155 generated reduced extrafollicular
and germinal center responses and did not produce high-
aﬃnity IgG1 antibodies. PU.1 is highly expressed in miR-
155-deﬁcient B cells and its overexpression in wild-type B
cells results in reduced numbers of IgG1-switched cells,
which indicates that miR-155 plays a key role in
antigen-driven B-cell maturation. PU.1 is a master gene
of the Ets transcriptional factor family that promotes cell
growth, diﬀerentiation and apoptosis thereby playing an
important role in hematopoiesis [see (38) for a review]. It is
both an oncogene (38) and a tumor suppressor gene that
promotes apoptosis. Here we show that LMP1-mediated
activation of miR-155 is correlated with diminished levels
of the PU.1 protein. Many mRNAs were predicted to
be direct targets of miR-155. A recent work reported
that miR-155 plays an important role in EBV-regulated
gene expression of the infected cells (34). It is thus possible
that the phenotypic alterations and the oncogenic
potentialities observed in miR-155-overexpressing mice
(14) are the result of deregulation of other targets in addi-
tion to PU.1. In silico analysis indicated that miR-155 may
target SOCS1 (39) and WEE1 (40) (G.G. and M.M.,
unpublished data), which would better account for
its oncogenic role. Probably, a miRNA can have two
or more targets or even diﬀerent targets depending on
the cellular context. Studies to elucidate the molecular
targets of miR-155 after LMP1 induction, and to
determine their reciprocal role during EBV infection and
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Figure 8. Semi-quantitative ChIP on the BIC promoter at indicated
times in DeFew cells after retroviral infection with a vector expressing
LMP1 or empty vector. ChIP assay of chromatin extracted at the
indicated times from DeFew cells infected with pBABEpuroLMP1 or
empty vector. (A) left panel: After immunoprecipitation with the indi-
cated antibodies, the DNA samples were puriﬁed and subjected to PCR
with speciﬁc primers amplifying the NF-kB site 1 region or NF-kB site
2 region. MW=molecular weight marker; p65=pAB anti NF-kB p65;
ti NF; H3=pAb anti Histone H3. Right panel: After immunoprecipi-
tation, the DNA samples were puriﬁed and subjected to PCR with
speciﬁc primers amplifying the G3PDH promoter region. (B) Graphic
of the results showed in panel (A; C) After immunoprecipitation with
mAb directed against the RNA pol II, the DNA samples were puriﬁed
and subjected to PCR with speciﬁc primers amplifying the
TATA box region. MW=molecular weight marker; pol II=mAB
anti RNA pol II; H3=pAb anti Histone H3.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6617EBV-mediated transformation are underway in our
laboratory.
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